AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
164.77
+3.14 (1.94%)
At close: Sep 3, 2026, 4:00 PM EDT
163.40
-1.37 (-0.83%)
After-hours: Sep 3, 2026, 4:52 PM EDT
AstraZeneca Employees
AstraZeneca had 95,100 employees as of December 31, 2025. The number of employees increased by 2,200 or 2.37% compared to the previous year.
Employees
95,100
Change (1Y)
2,200
Growth (1Y)
2.37%
Revenue / Employee
$645,279
Profits / Employee
$109,842
Market Cap
255.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 95,100 | 2,200 | 2.37% |
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
AZN News
- 8 hours ago - The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power - Nasdaq
- 1 day ago - Top Stock Reports for AMD, Costco & AstraZeneca - Nasdaq
- 2 days ago - AZN Looks 10.6% Undervalued on GF Value⢠as Dividend Remains Sustainable - GuruFocus
- 2 days ago - AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win - GuruFocus
- 2 days ago - AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Secure - GuruFocus
- 2 days ago - AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Attractive - GuruFocus
- 2 days ago - AZN Looks 10.5% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals - GuruFocus
- 2 days ago - AstraZeneca completes global license agreement for Zegfrovy in lung cancer - TheFly